Treatment-Resistant Depression study: ExAblate Neuro
Official title Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression
ClinicalTrials.gov ID: NCT07108257
What this study is testing
- What it's testing
- This study is testing whether MR‑guided focused ultrasound can be safe and may help people with bipolar depression that hasn’t improved with other treatments.
- Who it's for
- You may be able to join if you have bipolar depression that has not improved with other treatments.
- What's involved
- You would receive a special ultrasound treatment guided by MRI. You may have a few visits for scans and check‑ups.
- Time commitment
- The study lasts a few weeks, with several visits for scans and follow‑up appointments.
- Time commitment: about 26 months
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Men and women ≥18 and ≤65 years of age, inclusive.
- Patients who are competent and willing to give consent and able to attend study visits, as determined by both study Psychiatrist and the surgeon.
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of Bipolar Disorder, Type 1 or Type 2.
- A minimum score of 20 on the Hamilton Depression Rating Scale (HAMD) when depressed (at least 2 weeks of major depression at the time the HAMD is...
- Treatment refractory bipolar depression indicated by at least two recommended monotherapy treatments or at least one monotherapy treatment and...
You likely can't join if
- Patients with unstable cardiac status [e.g. Unstable angina pectoris on medication, Patients with documented myocardial infarction within six months...
- 3\. Laboratory biochemical evidence of abnormal bleeding and/or coagulopathy, including risk factors for intraoperative or postoperative bleeding...
- 5\. Untreated, uncontrolled sleep apnea. 6. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g.
- 7\. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment.
- 8\. Are participating or have participated in another clinical trial in the last 30 days.
- 9\. Patients unable to communicate with the investigator and staff. 10. Presence of significant cognitive impairment 11.
See the full eligibility criteria
- Men and women ≥18 and ≤65 years of age, inclusive.
- Patients who are competent and willing to give consent and able to attend study visits, as determined by both study Psychiatrist and the surgeon.
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of Bipolar Disorder, Type 1 or Type 2.
- A minimum score of 20 on the Hamilton Depression Rating Scale (HAMD) when depressed (at least 2 weeks of major depression at the time the HAMD is conducted).
- Treatment refractory bipolar depression indicated by at least two recommended monotherapy treatments or at least one monotherapy treatment and another combination treatment.
- Ability to provide informed consent/competent to make medical decisions.
- Patients with unstable cardiac status [e.g. Unstable angina pectoris on medication, Patients with documented myocardial infarction within six months, Congestive heart failure requiring medication (other than diuretic)...
- 3\. Laboratory biochemical evidence of abnormal bleeding and/or coagulopathy, including risk factors for intraoperative or postoperative bleeding (platelet count less than 100,000 per cubic millimeter or abnormal...
- 5\. Untreated, uncontrolled sleep apnea. 6. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g.
- 7\. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment.
- 8\. Are participating or have participated in another clinical trial in the last 30 days.
- 9\. Patients unable to communicate with the investigator and staff. 10. Presence of significant cognitive impairment 11. History of psychosis on clinical evaluation. 12.
- 14\. Chemical abuse or dependence within the previous six months
The study team makes the final eligibility decision.
Where it is enrolling
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 26 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Toronto, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.